公开(公告)号：US20210403557A1

公开(公告)日：2021-12-30

申请号：US17288641

申请日：2019-11-04

申请人： Mingmei CAI ,  Elliot K. CHARTASH ,  Jane Anne HEALY ,  Mallika LALA ,  Tommy Ruosi LI ,  Kapil MAYAWALA ,  Raluca Andreia PREDOIU ,  Sybil M.G. WILLIAMS ,  Zhen ZENG ,  Merck Sharp & Dohme Corp.

发明人： Mingmei Cai ,  Elliot K. Chartash ,  Jane Anne Healy ,  Mallika Lala ,  Tommy Ruosi Li ,  Kapil Mayawala ,  Raluca Andreia Predoiu ,  Sybil M.G. Williams ,  Zhen Zeng

IPC分类号： C07K16/28 ,  A61P35/00

摘要： The present invention relates to dosing regimens of an anti-TIGIT antibody useful for the treatment of cancer. In particular, the invention relates to the dosing regimen in a combination therapy which comprises administering an antibody of a Programmed Death 1 protein (PD-1) or Programmed Death Ligand 1 (PD-L1) and an anti-TIGIT antibody.

公开(公告)号：US20230192876A1

公开(公告)日：2023-06-22

申请号：US17772229

申请日：2020-10-29

申请人： Merck Sharp & Dohme Corp.

发明人： Elliot K. Chartash ,  Amy M. Beebe ,  Jason K. Cheung ,  Konstantin Dobrenkov ,  Claire H. Li ,  Richard Wnek

IPC分类号： C07K16/28 ,  A61P35/00 ,  A61K39/395 ,  A61K31/282 ,  A61K31/519

CPC分类号： C07K16/2878 ,  A61P35/00 ,  C07K16/2818 ,  C07K16/2827 ,  A61K39/3955 ,  A61K31/282 ,  A61K31/519 ,  A61K2039/505

摘要： The present invention relates to methods of treating cancer by administering an anti-CD27 antibody as a monotherapy or as a part of a combination thereof.

公开(公告)号：US20210347889A1

公开(公告)日：2021-11-11

申请号：US17289810

申请日：2019-11-04

申请人： Merck Sharp & Dohme Corp.

发明人： Anson Kunjachan Abraham ,  Elliot K. Chartash ,  Kenneth Emancipator ,  Rosario Garrido ,  Jane Anne Healy ,  Jonathan W. Juco ,  Diane Levitan ,  Qing Zhao

IPC分类号： C07K16/28 ,  A61P35/00

摘要： The present invention relates to dosing regimens of an anti-LAG3 antibody useful for the treatment of cancer. In particular, the invention relates to the dosing regimen in a combination therapy which comprises administering an antibody of a Programmed Death 1 protein (PD-1) or Programmed Death Ligand 1 (PD-L1) and an antibody of Lymphocyte-Activation Gene 3 (LAG3). The invention also provides a method for treating cancer in a patient comprising administering to the patient an anti-LAG3 antibody and an anti-PD-1 antibody, wherein the tumor tissue section of the patient is PD-L 1 expression positive, and optionally LAG3 expression positive.

公开(公告)号：US20210317214A1

公开(公告)日：2021-10-14

申请号：US17274531

申请日：2019-09-09

申请人： Merck Sharp & Dohme Corp.

发明人： Elliot K. Chartash ,  Terrill K. McClanahan ,  Jane Anne Healy

IPC分类号： C07K16/28 ,  A61P35/00

摘要： The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a Lymphocyte-Activation Gene 3 (LAG3) antagonist, and the use of the combination therapies for the treatment of non-microsatellite instability-high (non-MSI-H) or proficient mismatch repair (pMMR) colorectal cancer.